Twenty Novel Disease Group-Specific and 12 New Shared Macrophage Pathways in Eight Groups of 34 Diseases Including 24 Inflammatory Organ Diseases and 10 Types of Tumors

Abstract

The mechanisms underlying pathophysiological regulation of tissue macrophage (Mφ) subsets remain poorly understood. From the expression of 207 Mφ genes comprising 31 markers for 10 subsets, 45 transcription factors (TFs), 56 immunometabolism enzymes, 23 trained immunity (innate immune memory) enzymes, and 52 other genes in microarray data, we made the following findings. (1) When 34 inflammation diseases and tumor types were grouped into eight categories, there was differential expression of the 31 Mφ markers and 45 Mφ TFs, highlighted by 12 shared and 20 group-specific disease pathways. (2) Mφ in lung, liver, spleen, and intestine (LLSI-Mφ) express higher M1 Mφ markers than lean adipose tissue Mφ (ATMφ) physiologically. (3) Pro-adipogenic TFs C/EBPα and PPARγ and proinflammatory adipokine leptin upregulate the expression of M1 Mφ markers. (4) Among 10 immune checkpoint receptors (ICRs), LLSI-Mφ and bone marrow (BM) Mφ express higher levels of CD274 (PDL-1) than ATMφ, presumably to counteract the M1 dominant status via its reverse signaling behavior. (5) Among 24 intercellular communication exosome mediators, LLSI- and BM- Mφ prefer to use RAB27A and STX3 than RAB31 and YKT6, suggesting new inflammatory exosome mediators for propagating inflammation. (6) Mφ in peritoneal tissue and LLSI-Mφ upregulate higher levels of immunometabolism enzymes than does ATMφ. (7) Mφ from peritoneum and LLSI-Mφ upregulate more trained immunity enzyme genes than does ATMφ. Our results suggest that multiple new mechanisms including the cell surface, intracellular immunometabolism, trained immunity, and TFs may be responsible for disease group-specific and shared pathways. Our findings have provided novel insights on the pathophysiological regulation of tissue Mφ, the disease group-specific and shared pathways of Mφ, and novel therapeutic targets for cancers and inflammations.

A Novel Subset of CD95+ Pro-Inflammatory Macrophages Overcome miR155 Deficiency and May Serve as a Switch From Metabolically Healthy Obesity to Metabolically Unhealthy Obesity

“…Previous papers have reported similar findings, where double-positive macrophages are hypothesized to be pro-inflammatory ( 44 , 45 ). These results—suggesting M1 and M2 double-positive macrophages as a feature of ATMs in obesity conditions—are well correlated with our recent report ( 37 ).…”

“…As earlier mentioned, at least 30% of obese subjects eventually develop MUO ( 17 , 18 ). MUO is associated with an inflammatory environment perpetuated by ATMs ( 36 , 37 ). We sought to uncover, first, whether our MHO model transitioned to MUO over time; and, second, whether DKO mice at the MHO stage have increased pro-inflammatory macrophages and cytokine secretion.…”

A 12‐month pilot study outcomes of vagus nerve stimulation in Crohn's disease

“…This role is in accordance with Willemze et al 71 who recently hypothesized for an active role of VNS on changing phenotype/activity of intestinal ChAT + T cells during inflammation. This metabolic shift has already been discussed, 72‐74 arguing for a required metabolic reprogramming of immune cells during inflammation. We also suggest a role of VNS on the intestinal barrier, maybe on the microbiota because the VN is involved in the microbiota‐gut‐brain axis 75 .…”

Approaching Inflammation Paradoxes—Proinflammatory Cytokine Blockages Induce Inflammatory Regulators

“…We applied the -omics database mining methods and principles that we pioneered in 2004 (56,57) to this study. The detailed features and justification of this data mining approach were highlighted in Table 1 of our recent paper (47). We examined a comprehensive list of IGs collected in the InnateDB database (https://www.innatedb.com/), which had a total of 1367 genes.…”

“…Similar to single cytokine targeting Mab therapies discussed above, one of the current research strategies is to use genedeficient mouse models and transgenic mouse models to determine the dominant effects of these inflammatory regulators in disease models such as atherogenesis (29,46). Numerous disease risk factors have been identified to induce metabolic CVDs and other inflammatory diseases, such as hyperlipidemia, hyperglycemia, hyperhomocysteinemia, obesity, hypertension, and cigarette smoke (29,47). It has been documented that inflammation and metaflammation are evolutionally conserved; the underlying pathways are crosstalking (48).…”